Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $32.45B. The enterprise value is $38.39B.
Market Cap$32.45B
Enterprise Value$38.39B
Share Statistics
Teva Pharmaceutical has 1,146,838,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,146,838,700
Owned by Insiders0.41%
Owned by Institutions19.00%
Financial Efficiency
Teva Pharmaceutical’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -1.63%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-1.63%
Return on Capital Employed (ROCE)-0.01
Revenue Per Employee447.14K
Profits Per Employee-44.51K
Employee Count37,000
Asset Turnover0.42
Inventory Turnover2.82
Valuation Ratios
The current PE Ratio of Teva Pharmaceutical is 46.5. Teva Pharmaceutical’s PEG ratio is -0.08.
PE Ratio46.5
PS Ratio1.51
PB Ratio4.64
Price to Fair Value4.64
Price to FCF12.16
Price to Operating Cash Flow21.61
PEG Ratio-0.08
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of 16.54B and earned -1.64B in profits. Earnings per share was -1.45.
Revenue16.54B
Gross Profit8.06B
Operating Income-303.00M
Pretax Income-1.28B
Net Income-1.64B
EBITDA4.43B
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was 1.41B and capital expenditures -488.00M, giving a free cash flow of 918.00M billion.
Operating Cash Flow1.41B
Free Cash Flow918.00M
Free Cash Flow per Share0.80
Dividends & Yields
Teva Pharmaceutical pays an annual dividend of $0.085, resulting in a dividend yield of ―
Dividend Per Share$0.085
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.57
52-Week Price Change61.70%
50-Day Moving Average22.33
200-Day Moving Average18.08
Relative Strength Index (RSI)80.34
Average Volume (3m)12.60M
Important Dates
Teva Pharmaceutical upcoming earnings date is Feb 11, 2026, Before Open (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateFeb 11, 2026
Ex-Dividend DateNov 27, 2017
Financial Position
Teva Pharmaceutical as a current ratio of 0.98, with Debt / Equity ratio of 256.67%
Current Ratio0.98
Quick Ratio0.75
Debt to Market Cap0.71
Net Debt to EBITDA3.34
Interest Coverage Ratio-0.32
Taxes
In the past 12 months, Teva Pharmaceutical has paid 676.00M in taxes.
Income Tax676.00M
Effective Tax Rate-0.53
Enterprise Valuation
Teva Pharmaceutical EV to EBITDA ratio is 8.96, with an EV/FCF ratio of 19.37.
EV to Sales2.40
EV to EBITDA8.96
EV to Free Cash Flow19.37
EV to Operating Cash Flow15.57
Balance Sheet
Teva Pharmaceutical has $2.20B in cash and marketable securities with $17.09B in debt, giving a net cash position of -$14.89B billion.
Cash & Marketable Securities$2.20B
Total Debt$17.09B
Net Cash-$14.89B
Net Cash Per Share-$12.98
Tangible Book Value Per Share-$12.24
Margins
Gross margin is 49.60%, with operating margin of -1.83%, and net profit margin of -9.91%.
Gross Margin49.60%
Operating Margin-1.83%
Pretax Margin-7.76%
Net Profit Margin-9.91%
EBITDA Margin26.78%
EBIT Margin20.38%
Analyst Forecast
The average price target for Teva Pharmaceutical is $30.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.14
Price Target Upside5.90% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-0.25%
EPS Growth Forecast―